While CTLA-4 blockade has been shown to selectively deplete Tregs in a Fc-Fcγ-dependent manner in mouse models [38], it is unable to deplete Tregs in human cancers [39], highlighting the need and potential for modifications of Fc portions for enhanced Fc-mediated depletion of Tregs. Here, CTLA4 is linked to cancer.